Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20699003 | 0.91 | HIF1A (0.38) | HIF1APTGS2 | |
| SCHEMBL20698622 | 0.90 | HIF1A (0.50) | HIF1APTGS2NR1H4MEN1CYP1A2 | |
| SCHEMBL20698667 | 0.88 | HIF1A (0.37) | HIF1APTGS2NR1H4PPARGPPARA | |
| SCHEMBL20698668 | 0.88 | HIF1A (0.37) | HIF1APTGS2NR1H4MEN1CYP1A2 | |
| SCHEMBL20698995 | 0.88 | HIF1A (0.37) | HIF1ANR1H4MEN1KMT2A | |
| SCHEMBL20698896 | 0.86 | HIF1A (0.36) | HIF1A | |
| SCHEMBL20698888 | 0.85 | HIF1A (0.35) | HIF1A | |
| SCHEMBL20698899 | 0.84 | HIF1A (0.36) | HIF1APTGS2 | |
| SCHEMBL20698666 | 0.82 | HIF1A (0.48) | HIF1APTGS2 | |
| SCHEMBL19200309 | 0.82 | GAA (0.43) | HIF1AMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906880-B2 | Kind of isothiazole oxime ether-containing strobilurin derivatives and its preparation methods and application | NANKAI UNIVERSITY (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20190031627-A1 | A KIND OF ISOTHIAZOLE OXIME ETHER-CONTAINING STROBILURIN DERIVATIVES AND ITS PREPARATION METHODS AND APPLICATION | NANKAI UNIVERSITY (CN) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906880-B2 | Kind of isothiazole oxime ether-containing strobilurin derivatives and its preparation methods and application | STS, STAU1, CDV3 | HIF1A 3135/4885PTGS2 4753/4885NR1H4 3482/4885 |
| US-20190031627-A1 | A KIND OF ISOTHIAZOLE OXIME ETHER-CONTAINING STROBILURIN DERIVATIVES AND ITS PREPARATION METHODS AND APPLICATION | STS, CDV3, SALL4 | HIF1A 3136/4885PTGS2 4738/4885NR1H4 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.